View Future GrowthPfizer 과거 순이익 실적과거 기준 점검 0/6Pfizer의 수입은 연평균 -20.5%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 수입이 연평균 8.2% 증가했습니다. 매출은 연평균 2.2%의 비율로 감소해 왔습니다. Pfizer의 자기자본이익률은 9%이고 순이익률은 12.4%입니다.핵심 정보-20.49%순이익 성장률-20.77%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률16.25%매출 성장률-2.22%자기자본이익률8.97%순이익률12.38%다음 순이익 업데이트05 May 2026최근 과거 실적 업데이트Pfizer Inc. to Report Q1, 2026 Results on May 05, 2026Mar 24Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 05Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 04Pfizer Inc. to Report Q4, 2025 Results on Feb 03, 2026Dec 19Third quarter 2025 earnings released: EPS: US$0.62 (vs US$0.79 in 3Q 2024) Nov 05Pfizer Inc. to Report Q3, 2025 Results on Nov 04, 2025Sep 23모든 업데이트 보기Recent updatesPfizer Inc Announces Positive Topline Results from Phase 3 MagnetisMM-5 Study Evaluating Elrexfio as Monotherapy in Adults with Relapsed or Refractory Multiple MyelomaMay 01Pfizer Inc. Enters into Settlement Agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd for VYNDAMAXApr 30Fourth quarter dividend of US$0.43 announced Apr 26Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026Apr 23+ 1 more updateAstellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder CancerApr 20Pfizer Inc. to Report Q1, 2026 Results on May 05, 2026Mar 24Pfizer Inc. and Valneva SE Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor TrialMar 23Pfizer Inc Announces Positive Topline Results From Phase 3 Talapro-3 Study Of Talzenna In Combination With XtandiMar 19Pfizer Inc., Annual General Meeting, Apr 23, 2026Mar 13Pfizer Inc. Reports Positive Phase 2 Results for tilrekimig (PF-07275315) in Atopic DermatitisMar 10Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical TrialFeb 28Pfizer Inc. Announces U.S. FDA Grants Full Approval to its BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal CancerFeb 25Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal CancerFeb 17Pfizer Inc. Announced That FDA Has Accepted and Granted Priority Review for the Company's Supplemental Biologics License ApplicationFeb 06Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 05Full year 2025 earnings released: EPS: US$1.36 (vs US$1.42 in FY 2024) Feb 04Pfizer Inc. Reaffirms Earnings Guidance for the Full Year 2026Feb 03+ 1 more updateUpcoming dividend of US$0.43 per share Jan 16Pfizer Inc.'s BRAFTOVI Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal CancerJan 12Trial Date Has Been Set in MDL against Pfizer for Depo-Provera Overseen by Levin PapantonioJan 08New major risk - Revenue and earnings growth Jan 01Third quarter dividend of US$0.43 announced Dec 22Pfizer Inc. to Report Q4, 2025 Results on Feb 03, 2026Dec 19Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical TrialDec 17+ 2 more updatesPfizer Inc. Declares First-Quarter 2026 Dividend, Payable on March 6, 2026Dec 13Pfizer Inc. Announces Detailed Results from the Phase 3 HER2CLIMB-05 Trial of the Tyrosine Kinase Inhibitor TUKYSA (Tucatinib)Dec 11Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and AdolescentsDec 07U.S. FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder CancerNov 22Pfizer Inc. (NYSE:PFE) completed the acquisition of Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others.Nov 14Pfizer Reportedly Looks to Sell Stake in Pandemic Vaccine Partner BioNTechNov 13Third quarter 2025 earnings released: EPS: US$0.62 (vs US$0.79 in 3Q 2024) Nov 05Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025Nov 04Upcoming dividend of US$0.43 per share Nov 02Pfizer Inc. Receives Early Clearance from U.S. Federal Trade Commission for Metsera AcquisitionNov 01Pfizer Inc. and Astellas Pharma U.S. Inc. Announces Final Overall Survival Results from the Phase 3 EMBARK Study Evaluating XTANDIOct 20+ 2 more updatesPfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®?Oct 15Second quarter dividend of US$0.43 announced Oct 13Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin PapantonioSep 26Pfizer Inc. to Report Q3, 2025 Results on Nov 04, 2025Sep 23New major risk - Revenue and earnings growth Sep 23Pfizer Inc. (NYSE:PFE) agreed to acquire Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others for $5 billion.Sep 22+ 1 more updateArbutus Pharma Corp. and Genevant Sciences GmbH Provides Lawsuit UpdateSep 12Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust LitigationSep 11Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 FormulaSep 08Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSep 03Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European UnionAug 20New minor risk - Share price stability Aug 13PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAug 12Second quarter 2025 earnings released: EPS: US$0.51 (vs US$0.004 in 2Q 2024) Aug 06Pfizer Inc. Reaffirms Earnings Guidance for the Full Year of 2025Aug 05BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control PillJul 24Upcoming dividend of US$0.43 per share Jul 18Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDIJul 10First quarter dividend of US$0.43 announced Jul 02First quarter dividend of US$0.43 announced Jun 28Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi™? in Hemophilia A or B with InhibitorsJun 26+ 1 more updateArvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast CancerJun 06Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6May 30Case Management Conference in the Depo-Provera Legal Action Against Pfizer IncMay 29Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2May 23+ 1 more updateNew minor risk - Insider selling May 13First quarter dividend of US$0.43 announced May 03First quarter 2025 earnings released: EPS: US$0.52 (vs US$0.55 in 1Q 2024) May 03Pfizer Inc. Reaffirms Earnings Guidance for the Year 2025Apr 29Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder CancerApr 28+ 1 more updatePfizer Inc. Declares Second-Quarter 2025 Dividend, Payable on June 13, 2025Apr 24ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of DiseaseApr 17Pfizer Inc. Provides Update on Oral Glp-1 Receptor Agonist DanuglipronApr 14Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, IncApr 05European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract DiseaseApr 01Pfizer Inc. to Report Q1, 2025 Results on Apr 29, 2025Mar 18Pfizer Inc., Annual General Meeting, Apr 24, 2025Mar 14Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical TrialMar 11Senior VP recently sold CL$61m worth of stock Mar 11Independent Director recently bought CL$472m worth of stock Feb 15Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerFeb 14U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaFeb 13Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerFeb 11Pfizer Inc. Provides Earnings Guidance for the Year 2025Feb 07+ 1 more updateFull year 2024 earnings released: EPS: US$1.42 (vs US$0.38 in FY 2023) Feb 05Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater TrialFeb 03Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6Jan 27Upcoming dividend of US$0.43 per share Jan 17Pfizer Intends to Sell Approximately 700 Million Ordinary Shares in HaleonJan 15Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder CancerJan 10U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerDec 21매출 및 비용 세부 내역Pfizer가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이SNSE:PFECL 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 2562,5797,74612,96410,43728 Sep 2562,7859,79713,97310,13129 Jun 2563,83310,72814,00510,20530 Mar 2562,4647,86714,33310,43731 Dec 2463,6278,02014,77110,82229 Sep 2460,4334,27414,15510,49430 Jun 2456,223-2,59314,13910,61131 Mar 2455,946-28813,90810,56431 Dec 2359,5542,13413,83610,67901 Oct 2369,27410,46913,56111,42002 Jul 2378,42021,49413,39411,43502 Apr 2393,15429,03513,25811,62131 Dec 22101,17531,36612,20011,42602 Oct 2299,87829,95311,32511,26003 Jul 22101,27529,48110,03811,24303 Apr 2292,43325,4109,40010,66731 Dec 2181,28822,4139,56210,36003 Oct 2168,87719,4859,7149,97204 Jul 2155,11912,23611,6769,58904 Apr 2146,0849,03211,4549,18431 Dec 2041,6516,63011,4188,70927 Sep 2032,33421211,0068,08428 Jun 2034,7376,97710,5657,72729 Mar 2038,1379,42711,6377,71631 Dec 1940,90510,70712,7667,72129 Sep 1953,03916,21113,7557,89130 Jun 1953,65612,63814,0507,94831 Mar 1953,85911,46414,0047,91431 Dec 1840,8253,82412,1497,71330 Sep 1853,37323,80814,4817,82701 Jul 1853,24422,54514,4927,68601 Apr 1852,67321,74614,5097,67331 Dec 1752,54621,30514,6067,64501 Oct 1752,4719,79114,5467,84302 Jul 1752,3478,30814,6087,86102 Apr 1752,5987,28114,9597,82631 Dec 1652,8247,19814,8947,85802 Oct 1653,2436,27014,9567,65203 Jul 1652,2867,03614,6977,79703 Apr 1650,9927,61514,3397,78731 Dec 1548,8516,94814,3257,64627 Sep 1547,9228,36613,6407,36628 Jun 1548,1968,91313,6667,135양질의 수익: PFECL는 $11.4B 규모의 큰 일회성 손실이 있어 31st December, 2025까지 지난 12개월 재무 결과에 영향을 미쳤습니다.이익 마진 증가: PFECL의 현재 순 이익률 (12.4%)은 지난해 (12.6%)보다 낮습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: PFECL의 수익은 지난 5년 동안 연평균 20.5% 감소했습니다.성장 가속화: PFECL은 지난 1년 동안 수익이 감소하여 5년 평균과 비교할 수 없습니다.수익 대 산업: PFECL은 지난 1년 동안 수익이 감소(-3.4%)하여 Pharmaceuticals 업계 평균(6.9%)과 비교하기 어렵습니다.자기자본이익률높은 ROE: PFECL의 자본 수익률(9%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/01 10:42종가2026/04/30 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Pfizer Inc.는 44명의 분석가가 다루고 있습니다. 이 중 26명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David ToungArgus Research CompanyEmily FieldBarclaysKerry HolfordBerenberg41명의 분석가 더 보기
Pfizer Inc Announces Positive Topline Results from Phase 3 MagnetisMM-5 Study Evaluating Elrexfio as Monotherapy in Adults with Relapsed or Refractory Multiple MyelomaMay 01
Pfizer Inc. Enters into Settlement Agreements with Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd for VYNDAMAXApr 30
Pfizer Inc. Declares Second-Quarter Cash Dividend on Common Stock for 2026, Payable June 12, 2026Apr 23+ 1 more update
Astellas Pharma Inc. And Pfizer Inc. Receive U.S. FDA Priority Review For PADCEV And Keytruda As Perioperative Treatment For Muscle-Invasive Bladder CancerApr 20
Pfizer Inc. and Valneva SE Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 Valor TrialMar 23
Pfizer Inc Announces Positive Topline Results From Phase 3 Talapro-3 Study Of Talzenna In Combination With XtandiMar 19
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Results from the Phase 3 EV-304 Clinical TrialFeb 28
Pfizer Inc. Announces U.S. FDA Grants Full Approval to its BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal CancerFeb 25
Pfizer Inc. Announced That FDA Has Accepted and Granted Priority Review for the Company's Supplemental Biologics License ApplicationFeb 06
Pfizer Inc.'s BRAFTOVI Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal CancerJan 12
Astellas Pharma Inc. and Pfizer Inc. Announces Positive Topline Results from an Interim Analysis of the Phase 3 EV-304 Clinical TrialDec 17+ 2 more updates
Pfizer Inc. Announces Detailed Results from the Phase 3 HER2CLIMB-05 Trial of the Tyrosine Kinase Inhibitor TUKYSA (Tucatinib)Dec 11
Pfizer Inc. Presents Results from the Phase 3 BASIS Study Evaluating HYMPAVZI for Adults and AdolescentsDec 07
Pfizer Inc. (NYSE:PFE) completed the acquisition of Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others.Nov 14
Pfizer Inc. Receives Early Clearance from U.S. Federal Trade Commission for Metsera AcquisitionNov 01
Pfizer Inc. and Astellas Pharma U.S. Inc. Announces Final Overall Survival Results from the Phase 3 EMBARK Study Evaluating XTANDIOct 20+ 2 more updates
Pfizer Inc. Announces Positive Topline Results from the Phase 3 Her2climb-05 Trial of First-Line Combination Therapy with the Tyrosine Kinase Inhibitor Tukysa®?Oct 15
Hearing Against Pfizer Set for 29 September in Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen by Levin PapantonioSep 26
Pfizer Inc. (NYSE:PFE) agreed to acquire Metsera, Inc. (NasdaqGS:MTSR) from Arch Venture Partners, L.P., Population Health Partners, LLC and others for $5 billion.Sep 22+ 1 more update
Nastlaw LLC and Direct Purchaser Plaintiffs Announce Additional Settlements in Re Generic Pharmaceutical Pricing Antitrust LitigationSep 11
Pfizer Inc. and BioNTech SE Announce Topline Data Demonstrating Robust Immune Response with Their LP.8.1-Adapted COVID-19 Vaccine 2025-2026 FormulaSep 08
Olema Pharmaceuticals, Inc. Announces New Clinical Trial Agreement with Pfizer to Combine Palazestrant with Atirmociclib in ER+/HER2- Metastatic Breast CancerSep 03
Enanta Pharmaceuticals, Inc. Files Patent Infringement Suit Against Pfizer Inc. in the Unified Patent Court of the European UnionAug 20
PADCEV Plus KEYTRUDA Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After SurgeryAug 12
BioNTech SE and Pfizer Inc. Announces Collaboration with Pfizer to Develop COVID-19 Vaccine, BNT162b2 mRNA VaccineJul 25
Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control PillJul 24
Pfizer Inc. and Astellas Pharma Inc. Announce Positive Topline Results from the Overall Survival (OS) Analysis from the Phase 3 EMBARK Study Evaluating XTANDIJul 10
Pfizer Inc. Announces Positive Topline Phase 3 Results for Hympavzi™? in Hemophilia A or B with InhibitorsJun 26+ 1 more update
Arvinas and Pfizer Announce Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast CancerJun 06
Pfizer Inc. Announces Statically Significant and Clinically Significant Results from the Phase 3 BREAKWATER Trial Evaluating BRAFTOVI®? (Encorafenib) in Combination with Cetuximab and mFOLFOX6May 30
Nona Biosciences Collaboration Partner Pfizer Announces Presentation of Phase 1 Clinical Study Design on MesoC2May 23+ 1 more update
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder CancerApr 28+ 1 more update
ACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO to Include Adults Aged 50 to 59 At Increased Risk of DiseaseApr 17
Entwistle & Cappucci LLP Files Securities Class Action Against Cerevel Therapeutics Holdings, Inc., Bain Capital Investors, LLC and Pfizer, IncApr 05
European Commission Approves Pfizer's RSV Vaccine ABRYSVO to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract DiseaseApr 01
Arvinas, Inc. and Pfizer Inc. Announce Positive Topline Results from Phase 3 Veritac-2 Clinical TrialMar 11
Pfizer’s TALZENNA in Combination with XTANDI Improves Survival Outcomes in Metastatic Castration Resistant Prostate CancerFeb 14
U.S. FDA Approves Pfizer's ADCETRIS Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaFeb 13
Pfizer Inc. and Astellas Pharma Inc.'s PADCEV plus KEYTRUDA Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial CancerFeb 11
Pfizer’s Braftovi Combination Regimen Significantly Improved Progression-Free Survival and Overall Survival in Phase 3 Breakwater TrialFeb 03
Pfizer Inc. Announces Positive Results from the Phase 3 Breakwater Trial Evaluating Braftovi® (Encorafenib) in Combination with Cetuximab and Mfolfox6Jan 27
Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder CancerJan 10
U.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal CancerDec 21